Pruritus

Vifor Pharma and Cara Therapeutics announced the FDA has approved Korsuva for the treatment of moderate to severe pruritus in patients on hemodialysis.

Vifor Pharma and Cara Therapeutics announced the FDA has approved Korsuva for the treatment of moderate to severe pruritus in patients on hemodialysis.

Research from Johns Hopkins showed that although high symptom burden was linked to mortality for those awaiting kidney transplantation, survivors experienced improvement in nine of 11 symptoms within 3 months following the procedure.

Itch can have a substantial impact on quality of life, but is difficult to quantify, according to a research article in Science Advances.

The FDA accepted a new drug application for odevixibat for the treatment of pruritis in patients with progressive familial intrahepatic cholestasis, according to a press release.

Cara Therapeutics has submitted a new drug application to the FDA for its injectable form of difelikefalin, a medication designed to treat moderate-to-severe pruritus in patients on hemodialysis.

Children with Alagille syndrome who received 48 weeks of Maralixibat had clinically meaningful reduction in pruritus and improvements in quality of life, according to a presentation at The Liver Meeting Digital Experience.

In three phase 3 clinical trials, trifarotene 50 µg/g cream demonstrated efficacy and safety in the treatment of both facial and truncal acne, according to a poster presented at the American Academy of Dermatology virtual meeting.

Tralokinumab 300 mg showed significant improvements in pruritus and quality of life in atopic dermatitis patients in three phase 3 trials, according presentations at the American Academy of Dermatology virtual meeting.

A daily regimen of oral serlopitant was associated with a significant reduction in pruritus in a small cohort of patients with mild to moderate psoriasis, according to a study.